 Avrobio Inc NASDAQ: AVRO has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2 trial. In March, the FDA granted full approval to Sanofis SA NASDAQ: SNY Fabrazyme agalsidase beta after it received accelerated approval based on a surrogate endpoint of reduction of GL-3 inclusions in biopsied renal peritubular capillaries PTCs. 